ImmunoPrecise works on PolyTope mAb Therapy for Covid-19. Credit: Mark Fletcher-Brown on Unsplash.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

ImmunoPrecise Antibodies is set to use PolyTope mAb Therapy approach for the development of a universal COVID-19 therapy.

The approach builds on the company’s discovery platforms and artificial intelligence (AI) capabilities with its partner, EVQLV.

According to the company, the proposed curative treatments such as polyclonal, sensitised serum or individual monoclonal antibodies may not be effective after viral mutation.

ImmunoPrecise’s approach involves various mechanisms of the immune system, predicts mutations within the virus genome, along with additional characteristics for a maximum clinical benefit against existing and future strains.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ImmunoPrecise Antibodies coronavirus global project leader Ilse Roodink said: “Our PolyTope mAb Therapy perfectly combines the benefits of using well-defined and fully characterised monoclonal antibodies with the essential need for a multi-targeting strategy to tackle this quickly emerging virus, thereby significantly accelerating effective clinical application”.

In February this year, ImmunoPrecise initiated a research programme focused on the development of vaccine and therapeutic antibodies against SARS-CoV-2.